RGEN vs FTRE vs NTRA vs CRL vs TMO

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 8x trailing P/E (18. 7x forward), making it the more compelling value choice. Analysts rate Repligen Corporation (RGEN) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Thermo Fisher Scientific Inc.

(TMO) is the cheapest at 26. 8x versus Repligen Corporation at 147. 0x. On forward P/E, Charles River Laboratories International, Inc. is actually cheaper at 16. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -51. 3% for Fortrea Holdings Inc. (FTRE). Over 10 years, the gap is even starker: NTRA returned +1835% versus FTRE's -51. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.

(TMO) is the lower-risk stock at 1. 07β versus Fortrea Holdings Inc. 's 2. 38β — meaning FTRE is approximately 122% more volatile than TMO relative to the S&P 500. On balance sheet safety, Fortrea Holdings Inc. (FTRE) carries a lower debt/equity ratio of 12% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Thermo Fisher Scientific Inc.

(TMO) is the more profitable company, earning 15. 1% net margin versus -36. 2% for Fortrea Holdings Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus -13. 4% for NTRA. At the gross margin level — before operating expenses — NTRA leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Charles River Laboratories International, Inc.

(CRL) trades at 16. 0x forward P/E versus 61. 7x for Repligen Corporation — 45. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 0% to $654. 67.

In this comparison, TMO (0.

4% yield) pays a dividend. RGEN, FTRE, NTRA, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Natera, Inc.

(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17), +1835% 10Y return). Fortrea Holdings Inc. (FTRE) carries a higher beta of 2. 38 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NTRA: +1835%, FTRE: -51. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RGEN is a small-cap high-growth stock; FTRE is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; CRL is a small-cap quality compounder stock; TMO is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.